Search results for "Immunization"
Mixed findings on remdesivir for COVID-19, news on SARS-CoV-2 vaccines
Among other news this week, the NIH and the WHO released results from remdesivir trials, more negative findings were published for hydroxychloroquine, and ACP and Annals of Internal Medicine held a vaccine forum featuring Anthony S. Fauci, MD, MACP, and other experts.
https://immattersacp.org/weekly/archives/2020/10/20/2.htm
20 Oct 2020
ACIP releases updated vaccination schedule with several changes
Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) affect vaccinations for influenza and human papillomavirus, among others.
https://immattersacp.org/weekly/archives/2020/02/04/1.htm
4 Feb 2020
COVID-19 outcomes in health care workers and over the long term, vaccine evidence and uptake among the latest research
A study found that health care workers hospitalized with COVID-19 had shorter stays, while a survey showed high uncertainty about vaccination. Johnson & Johnson released efficacy data on a one-shot vaccine, and a study identified long-term decreases in function among COVID-19 survivors.
https://immattersacp.org/weekly/archives/2021/02/02/1.htm
2 Feb 2021
COVID-19 pill study; new vaccine recommendation plus data on waning efficacy, low risk of postvaccine myocarditis; updates on experimental treatments
A peer-reviewed study showed molnupiravir reduced hospitalizations and deaths in high-risk patients, the CDC favored mRNA vaccines over J&J's, experts explained potential issues with waning efficacy data, and a study quantified the low risk of myocarditis after vaccination.
https://immattersacp.org/weekly/archives/2021/12/21/1.htm
21 Dec 2021
Distribution plans, data on vaccines; NIH cautious on latest antibody treatment
The Advisory Committee on Immunization Practices chose clinicians and long-term care residents for priority vaccination, while ACP offered additional input on the topic. The NIH said that casirivimab plus imdevimab should not be standard of care, and the CDC offered recommendations on shortening quarantine.
https://immattersacp.org/weekly/archives/2020/12/08/1.htm
8 Dec 2020
New research on Pfizer pill, mental disorders after COVID-19, vaccine reactions
A manufacturer-funded trial quantified the effectiveness of nirmatrelvir/ritonavir in outpatients. A retrospective study found veterans had more mental health diagnoses and received more antidepressants, benzodiazepines, and opioids after COVID-19, while two other studies looked at reactions to second and third doses of the vaccines.
https://immattersacp.org/weekly/archives/2022/02/22/1.htm
22 Feb 2022
Treatment for high-risk COVID-19 patients, vaccine news, research on health messaging
An industry-funded study found benefit with bamlanivimab plus etesevimab for high-risk ambulatory COVID-19 patients, the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine, and two studies looked at COVID-19 messaging for minority populations.
https://immattersacp.org/weekly/archives/2021/07/20/1.htm
20 Jul 2021
New vaccine authorization and data, NIH on antibody treatment and ‘long COVID’
The Johnson & Johnson COVID-19 vaccine got an emergency use authorization, and an Israeli study provided more data on the Pfizer vaccine. The NIH recommended an antibody combo for outpatients and named long-term symptoms as post-acute sequelae of SARS-CoV-2 (PASC).
https://immattersacp.org/weekly/archives/2021/03/02/1.htm
2 Mar 2021
ACP observes National Influenza Vaccination Week, offers resources to physicians
The latest recommended immunization schedule for adults was reviewed and approved in part by ACP and is available online from Annals of Internal Medicine, as are other resources to help increase immunization rates.
https://immattersacp.org/weekly/archives/2017/12/05/6.htm
5 Dec 2017
One-fifth of COVID-19 patients taking nirmatrelvir-ritonavir had viral rebound
A small observational study of ambulatory patients with COVID-19 found that 1.8% of untreated patients tested positive again after testing negative, compared to 20.8% of those who took five days of nirmatrelvir-ritonavir.
https://immattersacp.org/weekly/archives/2023/11/14/4.htm
14 Nov 2023